Year: 2023

Takeda_Logo-4

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy OSAKA,...

logo-50

Global and China Automotive Gateway Industry Report 2023: Gateways are in a Transitional Phase from Centralized Gateways in Domain Centralized Architecture to Distributed Gateway in Zonal Architecture – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global and China Automotive Gateway Industry Report, 2023" report has been added to ResearchAndMarkets.com's offering. Automotive gateway research:...

IB_logo

Investment Bridge Announces Investment Opinion: Bridge Report on Ferrotec Holdings Corporation: The results for fiscal year March 2023 and earnings estimates for the fiscal year March 2024

NOTE TO EDITORS: The following is an investment opinion issued by Investment Bridge TOKYO--(BUSINESS WIRE)--Investment Bridge, one of Japan’s leading...